Multimodal imaging-based therapeutic fingerprints for optimizing personalized interventions: Application to neurodegeneration
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
&NA; Personalized Medicine (PM) seeks to assist the patients according to their specific treatment needs and potential intervention responses. However, in the neurological context, this approach is limited by crucial methodological challenges, such as the requirement for an understanding of the causal disease mechanisms and the inability to predict the brain's response to therapeutic interventions. Here, we introduce and validate the concept of the personalized Therapeutic Intervention Fingerprint (pTIF), which predicts the effectiveness of potential interventions for controlling a patient's disease evolution. Each subject's pTIF can be inferred from multimodal longitudinal imaging (e.g. amyloid‐&bgr;, metabolic and tau PET; vascular, functional and structural MRI). We studied an aging population (N = 331) comprising cognitively normal and neurodegenerative patients, longitudinally scanned using six different neuroimaging modalities. We found that the resulting pTIF vastly outperforms cognitive and clinical evaluations on predicting individual variability in gene expression (GE) profiles. Furthermore, after regrouping the patients according to their predicted primary single‐target interventions, we observed that these pTIF‐based subgroups present distinctively altered molecular pathway signatures, supporting the across‐population identification of dissimilar pathological stages, in active correspondence with different therapeutic needs. The results further evidence the imprecision of using broad clinical categories for understanding individual molecular alterations and selecting appropriate therapeutic needs. To our knowledge, this is the first study highlighting the direct link between multifactorial brain dynamics, predicted treatment responses, and molecular alterations at the patient level. Inspired by the principles of PM, the proposed pTIF framework is a promising step towards biomarker‐driven assisted therapeutic interventions, with additional important implications for selective enrollment of patients in clinical trials. HighlightsThe Personalized Therapeutic Intervention Fingerprint (pTIF) approach is proposed.pTIF vastly outperforms cognitive/clinical evaluations on predicting gene expression profiles.pTIF allows a reliable identification of patients with distinctive molecular alterations.pTIF may represent a turning‐point towards data‐driven assisted therapeutic Intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DPARSF: a MATLAB toolbox for “pipeline” data analysis of resting-state fMRI
Yan (2010) · Frontiers in System Neuroscience · doi:10.3389/fnsys.2010.00013 · Cited by 3,475
Exploring the brain network: A review on resting-state fMRI functional connectivity
van den Heuvel, M. P., & Hulshoff Pol, H. E. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.03.008 · Cited by 3,326 · cited 1×
“…of the brain's functional integrity, fractional amplitude of low-frequency fluctuation (fALFF) (Zou et al., 2008), regional homogeneity (ReHo) (Zang et al., 2004), and functional connectivity degree (van den Heuvel and Hulshoff Pol, 2010) measures were calculated for each considered brain region.”
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Regional homogeneity approach to fMRI data analysis.
Zang, Y., Jiang, T., Lu, Y., He, Y., & Tian, L. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2003.12.030 · Cited by 2,614
Neurodegenerative Diseases Target Large-Scale Human Brain Networks
Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L., & Greicius, M. D. (2009) · Neuron · doi:10.1016/j.neuron.2009.03.024 · Cited by 2,350
Inferring Regulatory Networks from Expression Data Using Tree-Based Methods
Huynh-Thu, V. A., Irrthum, A., Wehenkel, L., & Geurts, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012776 · Cited by 2,131
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
Self-citationControllability of structural brain networks
Gu, S., Pasqualetti, F., Cieslak, M., Telesford, Q. K., Yu, A. B., Kahn, A. E., Medaglia, J. D., Vettel, J. M., Miller, M. B., Grafton, S. T., et al. (2015) · Nature Communications · doi:10.1038/ncomms9414 · Cited by 912
Friston, K. J., Kahan, J., Biswal, B., & Razi, A. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.12.009 · Cited by 553 · cited 4×
“…spreading of normal and pathologic functional signals (Sotero et al., 2007; Valdes-sosa et al., 2011; Cabral et al., 2012; Sanz Leon et al., 2013; Friston et al., 2014; Iturria-Medina et al., 2014; Sanz-Leon et al., 2015; Stam et al., 2016) and, more recently, on the local interactions among…”
InfluentialMathematical framework for large-scale brain network modeling in The Virtual Brain
Sanz-Leon, P., Knock, S. A., Spiegler, A., & Jirsa, V. K. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.01.002 · Cited by 356
Optimally controlling the human connectome: the role of network topology
Betzel, R. F., Gu, S., Medaglia, J. D., Pasqualetti, F., & Bassett, D. S. (2016) · Scientific Reports · doi:10.1038/srep30770 · Cited by 247
Modeling the outcome of structural disconnection on resting-state functional connectivity
Cabral, J., Hugues, E., Kringelbach, M. L., & Deco, G. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.06.007 · Cited by 182 · cited 2×
“Dynamic network modeling has contributed significantly to our understanding of dissimilar brain mechanisms, such as the intricate spatiotemporal propagation of neuronal activity (Sotero et al., 2007; Valdes-sosa et al., 2011; Cabral et al., 2012; Sanz Leon et al., 2013; Friston et al., 2014; Sanz-Leon et al., 2015; St…”
Identification of neurodegenerative factors using translatome–regulatory network analysis
Brichta, L., Shin, W., Jackson-Lewis, V., Blesa, J., Yap, E.-L., Walker, Z., Zhang, J., Roussarie, J.-P., Alvarez, M. J., Califano, A., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4070 · Cited by 118 · cited 1×
“A crucial obstacle towards therapeutic advancement has been the challenge of understanding the key molecular mechanisms associated to brain deterioration (Brichta et al., 2015).”
Drug repositioning for Alzheimer’s disease based on systematic “omics” data mining
Zhang, M., Schmitt-Ulms, G., Sato, C., Xi, Z., Zhang, Y., Zhou, Y., St George-Hyslop, P., & Rogaeva, E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168812 · Cited by 108
Cited by
Preventing dementia by preventing stroke: The Berlin Manifesto
Hachinski, V., Einhäupl, K., Ganten, D., Alladi, S., Brayne, C., Stephan, B. C. M., Sweeney, M. D., Zlokovic, B., Iturria‐Medina, Y., Iadecola, C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.001 · Cited by 313
Self-citationHeterogeneity of Alzheimer’s disease: consequence for drug trials?
Devi, G., & Scheltens, P. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0455-y · Cited by 102
Adewale, Q., Khan, A. F., Carbonell, F., Iturria-Medina, Y., & Initiative, A. D. N. (2021) · eLife · doi:10.7554/elife.62589 · Cited by 44
Self-citationIturria-Medina, Y., Carbonell, F., Assadi, A., Adewale, Q., Khan, A. F., Baumeister, T. R., & Sanchez-Rodriguez, L. (2021) · Communications Biology · doi:10.1038/s42003-021-02133-x · Cited by 37
Self-citationKhan, A. F., Adewale, Q., Lin, S.-J., Baumeister, T. R., Zeighami, Y., Carbonell, F., Palomero-Gallagher, N., & Iturria-Medina, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41677-w · Cited by 28
Self-citation
Metadata
- Authors
- Iturria-Medina, Y., Carbonell, F. M., & Evans, A. C.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 179
- Pages
- 40-50
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W2808651428
- Cited by
- 41
- References
- 14
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.